OakChart

Anavex Life Sciences Corp

AVXLHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

1.06-0.07 (-6.19%)
2026-11-11 23:32 CET
Market cap
104.75 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-13.02 USD m
Free cash flow, TTM
-29.29 USD m
EPS diluted, TTM
-0.15
P/E
-
Compare

Price

AVXL against its 20, 50 and 200-day averages
2050200earnings
2.004.006.004.5M8.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AVXLclose 1.0620-day 1.2650-day 1.83200-day 2.931.06

85.4% under the 52-week high of 7.25 on 13 Nov 2025. 52-week low 1.05 on 11 Nov 2026. Last 15 sessions, 33.8% high to low

Volume 0.88× normal · the line is the 50-bar volume average

Profile

AVXL
52-week range, 0% of the way up
1.077.25

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

IndexRUT
Employees34
IPOAug 02, 2006
Beta1.25
ATR, 14d0.11
Rel volume0.88
Short float13.09%
Insider own1.71%
Inst own39.71%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap98.26M
Enterprise Value-20.07M
Income-13.02M
Sales0.00M
Book/sh1.21
Cash/sh1.28
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees34
IPOAug 02, 2006

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.87
P/C0.83
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio15.62
Current Ratio15.62
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.15
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y4.47% -3.79%
Sales past 3/5Y- -
EPS Y/Y TTM73.28%
Sales Y/Y TTM-
EPS Q/Q154.29%
Sales Q/Q-
EarningsAug 25 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own1.71%
Insider Trans0.00%
Inst Own39.71%
Inst Trans-3.40%
ROA-11.70%
ROE-12.80%
ROIC-11.58%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-15.54%
SMA50-42.06%
SMA200-63.88%
Trades-

Technical

Shs Outstand92.70M
Shs Float91.12M
Short Float13.09%
Short Ratio11.66
Short Interest11.92M
52W High7.25 -85.38%
52W Low1.07 -0.47%
Volatility10.08% 8.05%
ATR (14)0.11
RSI (14)29.15
Beta1.25
Rel Volume0.88
Avg Volume1.02M
Volume903,528

Performance

Perf Week-15.87%
Perf Month-28.38%
Perf Quarter-67.58%
Perf Half Y-65.58%
Perf YTD-70.22%
Perf Year-84.53%
Perf 3Y-81.53%
Perf 5Y-95.28%
Perf 10Y-67.58%
Recom1.00
Target Price20.00
Prev Close1.13
Price1.06
Change %-6.19%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
May 04, 2026InitiatedRRodman & RenshawBuy$20+1,786.8%
Dec 06, 2022DowngradeCCantor FitzgeraldOverweight → Neutral$16 → $11+937.7%
Jun 23, 2022InitiatedBBerenbergBuy$40+3,673.6%
Sep 23, 2021InitiatedBBTIG ResearchBuy$35+3,201.9%
Dec 16, 2020ReiteratedHH.C. WainwrightBuy$14 → $17+1,503.8%
Sep 28, 2020InitiatedLLadenburg ThalmannBuy$12+1,032.1%
Feb 27, 2020InitiatedCCantor FitzgeraldOverweight
Jun 18, 2019InitiatedJJanneyBuy
May 16, 2018ResumedMMaxim GroupBuy$5 → $7+560.4%
Mar 08, 2018InitiatedRROTH CapitalBuy$6+466.0%

Peers

Mkt cap
TickerCompanyMkt cap
CGTXCognition Therapeutics Inc64.42M
ABOSAcumen Pharmaceuticals Inc16.64M
ANVSAnnovis Bio Inc36.41M
ACIUAC Immune SA230.01M
PRTAProthena Corp Plc448.28M
ACOGAlpha Cognition Inc187.72M
INMBINmune Bio Inc34.05M
ACADAcadia Pharmaceuticals Inc3.17B
TSHATaysha Gene Therapies Inc1.39B
BIIBBiogen Inc37.46B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
IWCiShares Micro-Cap ETFAUM: 1.22B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-08-250.080-0.0800.00--
2026Q12026-02-09-0.060-0.123-0.0640.000.003
2025Q42025-11-25-0.110-0.150-0.1140.000.003
2025Q32025-08-12-0.160-0.142-0.1550.000.003
2025Q22025-05-13-0.130-0.150-0.1320.000.003
2025Q12025-02-12-0.140-0.170-0.1430.000.001
2024Q42024-12-23-0.140-0.163-0.1370.000.003
2024Q32024-08-06-0.140-0.160-0.1450.000.003
2024Q22024-05-09-0.130-0.110-0.1280.000.002
2024Q12024-02-07-0.110-0.145-0.1050.000.002
2023Q42023-11-27-0.120-0.147-0.1240.000.003
2023Q32023-08-08-0.140-0.167-0.1400.000.003
2023Q22023-05-09-0.170-0.188-0.1670.000.003
2023Q12023-02-07-0.170-0.188-0.1660.000.004
2022Q42022-11-28-0.180-0.165-0.1850.000.006
2022Q32022-08-09-0.160-0.154-0.1600.000.006

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.540-0.625-0.5380.00-
2020FY-0.450-0.510-0.4520.00-
2021FY-0.540-0.529-0.5430.000.00
2022FY-0.620-0.613-0.6240.000.00
2023FY-0.600-0.630-0.5950.000.00
2024FY-0.520-0.543-0.5150.000.00
2025FY-0.540-0.577-0.5400.000.00
2026FY--0.330---
2027FY--0.550---
2028FY-2.269--348.57
2029FY-4.660--713.06
2030FY-5.230--885.11

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-02-211000.000.000.00
2026Q4S2026-02-092000.000.000.00
2026Q4S2025-11-252000.000.000.00
2026Q4S2025-11-132000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4S2025-11-091000.000.000.00
2026Q4S2025-11-081000.000.000.00
2026Q4S2025-11-071000.000.000.00
2026Q4S2025-11-061000.000.000.00
2026Q4S2025-11-051000.000.000.00
2026Q4S2025-11-041000.000.000.00
2026Q4S2025-11-031000.000.000.00
2026Q4S2025-11-021000.000.000.00

Estimate history

EPS, annual-0.33-0.386-0.538-0.452-0.543-0.624-0.595-0.515-0.544-0.1516
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.145-0.137-0.143-0.132-0.155-0.114-0.064-0.0580.084
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual43.33145.93352.6562.04575.91877.94382.06784.79686.66992.697
Period201720182019202020212022202320242025MRQ
Shares, quarterly84.79684.79684.98585.33485.41286.66992.67292.69792.697
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other17.3751.4152.8855.7650.9942.0031.0929.1119.33
Research and Development11.4437.5941.8443.7237.9232.9825.2322.2613.34
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-17.37-51.41-52.88-55.76-50.99-42.00-31.09-29.11-19.33
Interest Expense0.000.000.000.960.000.000.000.150.03
Unusual Expense0.000.000.000.000.000.000.00-0.120.00
Net Income Before Taxes-13.11-47.02-45.29-50.22-50.94-42.19-30.63-28.68-19.01
Income Taxes-0.09-0.65-2.29-2.71-2.96-4.28-4.35-2.38-1.76
Consolidated Net Income-13.02-46.38-43.00-47.51-47.98-37.91-26.28-26.29-17.25
Net Income From Continuing Operations-13.02-46.38-43.00-47.51-47.98-37.91-26.28-26.29-17.25
Net Income-13.02-46.38-43.00-47.51-47.98-37.91-26.28-26.29-17.25
EPS (Recurring)-0.14-0.54-0.52-0.60-0.62-0.54-0.45-0.54-0.39
EPS (Basic, Before Extraordinaries)-0.15-0.54-0.52-0.60-0.62-0.54-0.45-0.54-0.39
EPS (Diluted)-0.15-0.54-0.52-0.60-0.62-0.54-0.45-0.54-0.39
EBITDA-17.37-51.41-52.88-55.76-50.99-42.00-31.09-29.11-19.33
Non-Operating Income (Expense)4.264.387.586.500.04-0.190.460.460.35
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-12.1711.557.4612.9314.526.013.564.694.36
Shares Outstanding92.7086.6784.8082.0777.9475.9262.0552.6545.93
Market Capitalization104.75104.75481.64536.78804.371,358.95273.87166.38121.92

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other-6.746.486.7810.8414.4612.5113.5914.34
Research and Development-4.714.194.667.299.969.8910.4511.55
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income6.74-6.48-6.78-10.84-14.46-12.51-13.59-14.34
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.06
Net Income Before Taxes7.79-5.37-5.70-9.84-13.37-11.29-12.52-12.44
Income Taxes-0.03-0.03-0.01-0.01-0.13-0.10-0.41-0.82
Consolidated Net Income7.82-5.34-5.68-9.82-13.24-11.20-12.11-11.62
Net Income From Continuing Operations7.82-5.34-5.68-9.82-13.24-11.20-12.11-11.62
Net Income7.82-5.34-5.68-9.82-13.24-11.20-12.11-11.62
EPS (Recurring)0.08-0.06-0.06-0.11-0.16-0.13-0.14-0.14
EPS (Basic, Before Extraordinaries)0.08-0.06-0.06-0.11-0.16-0.13-0.14-0.14
EPS (Diluted)0.08-0.06-0.06-0.11-0.16-0.13-0.14-0.14
EBITDA6.74-6.48-6.78-10.84-14.46-12.51-13.59-14.34
Non-Operating Income (Expense)1.051.121.091.011.091.221.071.95
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-17.080.310.873.723.421.141.623.57
Shares Outstanding92.7092.7092.6786.6785.4185.3384.9984.80
Market Capitalization104.75284.50318.08764.45787.13729.85910.92481.64

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments102.58132.19151.02149.16152.1129.2522.1922.9327.44
Short Term Receivables0.812.452.713.199.144.852.641.870.01
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.430.930.650.350.360.440.501.250.34
Total Current Assets103.81135.57154.39152.70161.6034.5425.3326.0527.79
Net Property, Plant & Equipment0.000.000.000.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.020.000.000.150.05
Total Assets103.81135.57154.39152.70161.6234.5425.3326.2127.84
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.000.000.000.00
Accounts Payable4.259.634.323.824.743.993.522.963.58
Other Current Liabilities4.705.688.216.396.063.321.520.930.00
Total Current Liabilities8.9515.3012.5310.2110.807.315.043.883.58
Long Term Debt0.000.000.000.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00-0.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities8.9515.3012.5310.2110.807.315.043.883.58
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity94.87120.26141.85142.49150.8227.2420.2922.3224.25
Total Shareholders Equity94.87120.26141.85142.49150.8227.2420.2922.3224.25
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity94.87120.26141.85142.49150.8227.2420.2922.3224.25
Total Liabilities & Stockholders Equity103.81135.57154.39152.70161.6234.5425.3326.2127.84
Book Value Per Share1.091.421.731.831.990.440.390.490.56
Tangible Book Value Per Share1.091.421.731.831.990.440.390.490.56
Full-Time Employees344240382520161310
Price to Book Ratio0.933.713.635.659.0410.368.205.257.44
Return on Assets-38.75-29.66-30.94-30.53-38.65-87.79-105.80-63.85-72.10
Return on Equity-43.11-32.81-33.41-32.71-42.58-110.59-128.96-74.08-88.09
Return on Invested Capital-48.89-35.76-33.49-33.67-25.14-96.49-129.60-77.29-55.50
Quick Ratio11.608.8612.3214.9514.974.735.036.717.75
Current Ratio11.608.8612.3214.9514.974.735.036.717.75

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-13.02-46.38-43.00-47.51-47.98-37.91-26.28-26.29-17.25
Depreciation--------0.00
Other Funds (Non Cash)-11.9411.559.4417.2118.388.234.886.425.42
Funds from Operations-24.96-34.83-33.56-30.29-29.60-29.68-21.40-19.88-11.84
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-4.33-4.222.752.505.36-0.710.121.30-0.85
Cash from Operating Activities-29.29-39.04-30.81-27.79-24.24-30.38-21.29-18.58-12.68
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock46.9012.1411.9729.6521.29153.2428.3517.838.17
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock46.9012.1411.9729.6521.29153.2428.3517.838.17
Proceedsfrom Stock Options45.639.2011.2827.8820.28147.6728.3517.838.17
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.45-2.710.000.000.000.000.000.000.00
Other Financing Activities Uses-0.45-2.710.000.000.000.000.000.000.00
Cash from Financing Activities46.459.4311.9729.6521.29153.2428.3517.838.17
Net Change in Cash17.16-29.61-18.841.87-2.95122.867.06-0.75-4.51
Free Cash Flow-29.29-39.04-30.81-27.79-24.24-30.38-21.29-18.58-12.68
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments118.33127.42131.75102.58101.16115.77
Short Term Receivables0.990.930.840.810.820.67
Inventories0.000.000.000.000.000.00
Other Current Assets0.820.410.400.430.450.70
Total Current Assets120.14128.77132.99103.81102.43117.14
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets120.14128.77132.99103.81102.43117.14
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable3.662.522.644.256.747.00
Other Current Liabilities4.044.543.734.704.7310.38
Total Current Liabilities7.697.066.378.9511.4717.38
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities7.697.066.378.9511.4717.38
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity112.45121.71126.6294.8790.9699.76
Total Shareholders Equity112.45121.71126.6294.8790.9699.76
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity112.45121.71126.6294.8790.9699.76
Total Liabilities & Stockholders Equity120.14128.77132.99103.81102.43117.14
Book Value Per Share1.211.311.371.091.061.17
Tangible Book Value Per Share1.211.311.371.091.061.17
Full-Time Employees---34--
Price to Book Ratio0.932.253.258.367.896.57
Return on Assets-11.70-27.72-31.08-38.75-39.47-36.00
Return on Equity-12.80-30.78-33.63-43.11-43.63-40.13
Return on Invested Capital6.96-4.39-4.49-10.36-14.56-11.22
Quick Ratio15.6218.2420.8711.608.936.74
Current Ratio15.6218.2420.8711.608.936.74

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income7.82-5.34-5.68-9.83-13.24-11.20
Other Funds (Non Cash)-17.080.311.113.724.321.45
Funds from Operations-9.26-5.02-4.57-6.11-8.92-9.75
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.160.58-2.58-2.50-3.543.89
Cash from Operating Activities-9.10-4.44-7.15-8.60-12.46-5.86
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.1136.3210.460.120.85
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.1136.3210.460.120.85
Proceedsfrom Stock Options0.0036.430.009.200.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.45-2.260.00
Other Financing Activities Uses0.000.000.00-0.45-2.260.00
Cash from Financing Activities0.000.1136.3210.02-2.140.85
Net Change in Cash-9.10-4.3329.171.41-14.61-5.00
Free Cash Flow-9.10-4.44-7.15-8.60-12.46-5.86

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.09%11.9M91.1M1.04M
2026-10-1513.77%12.5M91.1M1.01M
2026-09-3014.89%13.6M91.1M899.57K
2026-09-1515.73%14.3M91.1M1.07M
2026-08-3115.25%13.9M91.1M1.16M
2026-08-1415.71%14.1M89.8M1.21M
2026-07-3116.06%14.4M89.8M1.21M
2026-07-1515.75%14.1M89.8M1.18M
2026-06-3015.85%14.2M89.8M1.22M
2026-06-1519.52%17.5M89.8M1.38M
2026-05-2920.98%18.8M89.8M1.36M
2026-05-1521.42%19.2M89.8M1.34M
2026-04-3021.18%19.0M89.8M1.44M
2026-04-1521.11%19.0M89.8M1.52M
2026-03-3121.48%19.3M89.7M1.60M
2026-03-1323.65%21.2M89.7M1.53M
2026-02-2722.71%20.4M89.7M1.79M
2026-02-1322.90%20.5M89.7M2.53M
2026-01-3023.08%20.0M86.5M2.69M
2026-01-1522.89%19.8M86.5M2.62M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.000.750.1513.2884.000.000.790-0.0270.000
call2.000.000.050.043.11772.000.000.195-0.0080.001
call3.000.000.050.104.5881530.000.158-0.0110.000
call4.000.000.750.005.6940.000.000.146-0.0120.000
call5.000.000.050.005.9560.000.000.133-0.0130.000
put1.000.000.500.058.97551.000.00-0.210-0.0260.000
put2.000.501.250.107.8750.000.00-0.806-0.0090.000
put3.001.502.250.859.3719.000.00-0.840-0.0110.000
put4.002.303.500.0014.2980.000.00-0.854-0.0120.000
put5.003.304.500.0014.9760.000.00-0.863-0.0120.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-064Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-038-KCurrent report2026-11-01SEC
2026-11-028-KCurrent report2026-10-28SEC
2026-10-208-KCurrent report2026-10-20SEC
2026-10-158-KCurrent report2026-10-15SEC
2026-10-053Initial statement of beneficial ownership of securities2026-09-24SEC
2026-10-053Initial statement of beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-288-KCurrent report2026-09-24SEC
2026-09-21DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2026-09-18DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2026-09-17DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2026-09-15DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-15DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2026-09-14DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-10DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2026-09-10DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-09-09DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2026-09-08DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-04DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-04DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2026-09-03DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2026-09-028-KCurrent report2026-09-02SEC
2026-09-02DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2026-09-01DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-31DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.8.69%
VANGUARD CAPITAL MANAGEMENT LLC4.38%
TWO SIGMA INVESTMENTS, LP3.29%
GEODE CAPITAL MANAGEMENT, LLC2.45%
STATE STREET CORP2.07%
FEDERATED HERMES, INC.1.16%
AQR CAPITAL MANAGEMENT LLC1.04%
VANGUARD PORTFOLIO MANAGEMENT LLC1.02%
Summit Financial, LLC0.98%
GOLDMAN SACHS GROUP INC0.96%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.16%
iShares Russell 2000 ETF2.61%
Federated Hermes MDT Small Cap Core Fund2.21%
VANGUARD EXTENDED MARKET INDEX FUND1.12%
Fidelity Small Cap Index Fund1.08%
iShares Russell 2000 Value ETF0.80%
iShares Biotechnology ETF0.68%
VANGUARD RUSSELL 2000 INDEX FUND0.57%
Schwab U.S. Small-Cap ETF0.47%
Fidelity Extended Market Index Fund0.43%

OakChart. AVXL. Cached 15 minutes.

Some panels did not load: insider.